shao-et-al-2022-multi-cancer-early-detection-test-sensitivity-for-cancers-with-and-without-current-population-level.pdf (511.91 kB)
Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options.
journal contributionposted on 2023-06-08, 09:51 authored by Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer, Mohan Tummala
There are four solid tumors with common screening options in the average-risk population aged 21 to 75 years (breast, cervical, colorectal, and, based on personalized risk assessment, prostate), but many cancers lack recommended population screening and are often detected at advanced stages when mortality is high. Blood-based multi-cancer early detection tests have the potential to improve cancer mortality through additional population screening. Reported here is a post-hoc analysis from the third Circulating Cell-free Genome Atlas substudy to examine multi-cancer early detection test performance in solid tumors with and without population screening recommendations and in hematologic malignancies. Participants with cancer in the third Circulating Cell-free Genome Atlas substudy analysis were split into three subgroups: solid screened tumors (breast, cervical, colorectal, prostate), solid unscreened tumors, and hematologic malignancies. In this post hoc analysis, sensitivity is reported for each subgroup across all ages and those aged ⩾50 years overall, by cancer, and by clinical cancer stage. Aggregate sensitivity in the solid screened, solid unscreened, and hematologic malignancy subgroups was 34%, 66%, and 55% across all cancer stages, respectively; restricting to participants aged ⩾50 years showed similar aggregate sensitivity. Aggregate sensitivity was 27%, 53%, and 60% across stages I to III, respectively. Within the solid unscreened subgroup, aggregate sensitivity was >75% in 8/18 cancers (44%) and >50% in 13/18 (72%). This multi-cancer early detection test detected cancer signals at high (>75%) sensitivity for multiple cancers without existing population screening recommendations, suggesting its potential to complement recommended screening programs.Clinical trial identifier: NCT02889978.
Crick (Grant ID: 10169, Grant title: Swanton FC001169)
cancer screeningearly detectionepidemiology and preventionliquid biopsyMulti-cancer early detectionprecision medicineFemaleHumansMaleCervix UteriColorectal NeoplasmsEarly Detection of CancerHematologic NeoplasmsMass ScreeningNeoplasm StagingYoung AdultAdultMiddle AgedAgedSwanton FC0011691103 Clinical SciencesOncology & Carcinogenesis